Supplemental Adjuvants for Intracellular Nutrition and Treatment
NCT00893724 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2011-07-20
Summary
Nutritional supplements have an augmentative effect on the outcomes of standard treatment of diabetic macular edema (DME) and Neovascular Age-Related Macular Degeneration (NAMD).
Conditions
- Neovascular Age-related Macular Degeneration
- Diabetic Macular Edema
Interventions
- DRUG
-
Neutral pills with no medicinal effect
Neutral pills with no medicinal effect
- DIETARY_SUPPLEMENT
-
Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals
Inosine \[SR\] - 1\[500mg\] tablet bid Tocopherols \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] - combination capsule bid Sustained Release Niacinamide - 1 \[750mg\] tablet bid Vitamin C - 1 \[1000mg\] sustained release tablet bid N-acetyl Cysteine - 1 \[600mg\] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid
- DRUG
-
Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline
Inosine \[SR\] - 1 \[500mg\] tablet bid Tocopherol \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] combination capsule bid Sustained Release Niacinamide 1 \[750mg\] tablet bid Vitamin C 1 \[1000mg\] sustained release tablet bid N-acetyl Cysteine 1 \[600mg\] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid Minocycline 1 \[50mg\] tablet qd
Sponsors & Collaborators
-
West Virginia University
collaborator OTHER -
Mid-Atlantic Retina Consultations, Inc.
lead OTHER
Principal Investigators
-
Nabil M Jabbour, MD, FACS · M.A.R.C.
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-06-30
- Primary Completion
- 2011-08-31
- Completion
- 2011-09-30
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration
NCT02564978 ·Status: COMPLETED ·Phase: PHASE2
-
MMP-9 Inhibition for Recalcitrant Wet AMD
NCT04504123 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
NCT01601483 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration
NCT00100009 ·Status: COMPLETED ·Phase: PHASE3
-
Visudyne® in Occult (VIO)
NCT00121407 ·Status: COMPLETED ·Phase: PHASE3
-
Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema
NCT01194674 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)
NCT00211419 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration
NCT01922128 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
NCT00913744 ·Status: COMPLETED ·Phase: PHASE2
-
X-82 to Treat Age-related Macular Degeneration
NCT02348359 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
NCT01941082 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
NCT05904691 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
NCT00658619 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
NCT01414153 ·Status: COMPLETED ·Phase: PHASE2
-
Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
NCT01570790 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration
NCT00464347 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD
NCT00383370 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
NCT01423149 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD
NCT00320775 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema
NCT00656643 ·Status: COMPLETED ·Phase: PHASE2
-
Minocycline Treatment in Retinitis Pigmentosa
NCT04068207 ·Status: COMPLETED ·Phase: PHASE2
-
Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment
NCT07133438 ·Status: RECRUITING ·Phase: PHASE4
-
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
NCT01573572 ·Status: COMPLETED ·Phase: PHASE4
-
Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)
NCT00473928 ·Status: COMPLETED ·Phase: PHASE1
-
NT-101 Topical Ophthalmic Solution in Patients With Wet AMD
NCT06704009 ·Status: COMPLETED ·Phase: PHASE1/PHASE2